Overview

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study was a randomized strategy trial conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but did not otherwise meet criteria to initiate HAART for their own health. The study was designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduced morbidity and mortality compared to discontinuation and re-initiation of HAART when protocol specified criteria were met.
Phase:
Phase 4
Details
Lead Sponsor:
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Anti-Retroviral Agents